On ECHEMI
Home > Drugs > Yantai Dongcheng Beifang Pharmaceutical Co., Ltd.
Yantai Dongcheng Beifang Pharmaceutical Co., Ltd.
  • Founded in:

    1993-02-26
  • Country:

    China China
  • Address:

    No. 22, Tianjin North Road, Economic and Technological Development Zone, Yantai City, Shandong Province
  • Tax NO.:

    913706006134231455
  • Registered Funds:

    50 million yuan
  • Website:

  • Email:

Related Drugs
Urokinase for injection
An enzyme that activates plasminogen extracted from fresh human urine, a sterile lyophilized product with appropriate amounts of stabilizers and excipients.
Name Description Content CAS NO. Registered Holders
An enzyme that activates plasminogen, extracted from fresh human urine

It acts directly on the endogenous fibrinolytic system, catalyzes the cleavage of plasminogen into plasmin, degrades fibrin clots, fibrinogen in the blood circulation, coagulation factor V and coagulation factor VIII, etc., and exerts a thrombolytic effect; increases vascular ADPase activity, inhibits ADP-induced platelet aggregation, and prevents thrombosis; increases plasmin activity in the patient's body; reduces plasma fibrin or fibrinogen levels and increases their degradation products; shows that the thrombolytic effect is related to the drug dose and the time window of administration; has low toxicity, no obvious antigenicity, teratogenicity, carcinogenicity and mutagenicity, but may increase the risk of bleeding.

More

It acts directly on the endogenous fibrinolytic system, catalyzes the cleavage of plasminogen into plasmin, degrades fibrin clots, fibrinogen in the blood circulation, coagulation factor V and coagulation factor VIII, etc., and exerts a thrombolytic effect; increases vascular ADPase activity, inhibits ADP-induced platelet aggregation, and prevents thrombosis; increases plasmin activity in the patient's body; reduces plasma fibrin or fibrinogen levels and increases their degradation products; shows that the thrombolytic effect is related to the drug dose and the time window of administration; has low toxicity, no obvious antigenicity, teratogenicity, carcinogenicity and mutagenicity, but may increase the risk of bleeding.

0
Troxerutin for injection
Troxerutin
Name Description Content CAS NO. Registered Holders
Troxerutin

This product can inhibit platelet aggregation and prevent thrombosis. It can also counteract vascular damage caused by 5-hydroxytryptamine and bradykinin, increase capillary resistance, reduce capillary permeability, and prevent edema caused by increased vascular permeability.

More

This product can inhibit platelet aggregation and prevent thrombosis. It can also counteract vascular damage caused by 5-hydroxytryptamine and bradykinin, increase capillary resistance, reduce capillary permeability, and prevent edema caused by increased vascular permeability.

7085-55-4 24
Troxerutin for injection
Troxerutin
Name Description Content CAS NO. Registered Holders
Troxerutin

This product can inhibit platelet aggregation and prevent thrombosis. It can also counteract vascular damage caused by 5-hydroxytryptamine and bradykinin, increase capillary resistance, reduce capillary permeability, and prevent edema caused by increased vascular permeability.

More

This product can inhibit platelet aggregation and prevent thrombosis. It can also counteract vascular damage caused by 5-hydroxytryptamine and bradykinin, increase capillary resistance, reduce capillary permeability, and prevent edema caused by increased vascular permeability.

7085-55-4 24
L-Carnitine for Injection
The main ingredient of this product is L-carnitine.
Name Description Content CAS NO. Registered Holders
L-carnitine

Promote lipid metabolism, increase energy production, improve energy supply to tissues and organs, participate in drug detoxification, oxidation of medium-chain fatty acids, oxidation of fatty acid peroxidase, buffer the ratio of bound coenzyme A to free coenzyme A, generate energy from ketones, pyruvate, and amino acids (including branched-chain amino acids), remove excessive coenzyme A toxicity, and regulate blood ammonia concentration.

More

Promote lipid metabolism, increase energy production, improve energy supply to tissues and organs, participate in drug detoxification, oxidation of medium-chain fatty acids, oxidation of fatty acid peroxidase, buffer the ratio of bound coenzyme A to free coenzyme A, generate energy from ketones, pyruvate, and amino acids (including branched-chain amino acids), remove excessive coenzyme A toxicity, and regulate blood ammonia concentration.

541-15-1 17
Urinary gonadotropin for injection
This product is a sterile product extracted from the urine of menopausal women and refined by adding appropriate excipients and freeze-drying. It contains two biologically active ingredients, follicle-stimulating hormone and luteinizing hormone, with a ratio of about 1. The excipients of this product are dextran 40, mannitol; pH regulator hydrochloric acid or (and) sodium hydroxide.
Name Description Content CAS NO. Registered Holders
Glycoprotein gonadotropin

It has the function of follicle-stimulating hormone (FSH), promoting the development and maturation of ovarian follicles and testicular production and secretion of steroid hormones. It can make the endometrium of women proliferate, and promote the development of seminiferous tubules, spermatogenic cell division and sperm maturation in men.

More

It has the function of follicle-stimulating hormone (FSH), promoting the development and maturation of ovarian follicles and testicular production and secretion of steroid hormones. It can make the endometrium of women proliferate, and promote the development of seminiferous tubules, spermatogenic cell division and sperm maturation in men.

0
Dextran

This product is a gonadotropin drug. It mainly has the function of follicle-stimulating hormone (FSH), promoting the development and maturation of ovarian follicles and testicular production and secretion of steroid hormones. It causes endometrial hyperplasia in women and promotes the development of seminiferous tubules, spermatogenic cell division and sperm maturation in men.

More

This product is a gonadotropin drug. It mainly has the function of follicle-stimulating hormone (FSH), promoting the development and maturation of ovarian follicles and testicular production and secretion of steroid hormones. It causes endometrial hyperplasia in women and promotes the development of seminiferous tubules, spermatogenic cell division and sperm maturation in men.

9004-54-0 16
Mannitol

This product is a gonadotropin drug. It mainly has the function of follicle-stimulating hormone (FSH), promoting the development and maturation of ovarian follicles and testicular production and secretion of steroid hormones. It causes endometrial hyperplasia in women and promotes the development of seminiferous tubules, spermatogenic cell division and sperm maturation in men.

More

This product is a gonadotropin drug. It mainly has the function of follicle-stimulating hormone (FSH), promoting the development and maturation of ovarian follicles and testicular production and secretion of steroid hormones. It causes endometrial hyperplasia in women and promotes the development of seminiferous tubules, spermatogenic cell division and sperm maturation in men.

87-78-5 31
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.